Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004103 · ClinicalTrials.gov registry record · Phase 2
Combination Chemotherapy Followed by Surgery in Treating Patients With Stomach Cancer
A Phase 2 study, sponsored by NYU Langone Health.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00004103 is a Phase 2 study that has completed, run by NYU Langone Health.
The verdict
NCT00004103, a Phase 2 study, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and combining chemotherapy with surgery may kill more tumor cells. PURPOSE: This phase II trial is studying how well irinotecan and cisplatin followed by surgery, floxuridine, and cisplatin work in treating patients with stomach cancer.
Interventions
- DRUG cisplatin
- PROCEDURE conventional surgery
- PROCEDURE adjuvant therapy
- DRUG floxuridine
- DRUG irinotecan hydrochloride
Trial Details
| Field | Value |
|---|---|
| Start Date | 1998-07 |
| Est. Completion | 2009-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00004103
The ClinicalTrials.gov registry entry for NCT00004103 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which cisplatin is the first listed.
NCT00004103 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00004103 about?
NCT00004103 is a clinical study titled "Combination Chemotherapy Followed by Surgery in Treating Patients With Stomach Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and combining chemotherapy with surgery may kill more tumor cells. PURPOSE: This phase II trial is studying how well irinotecan and cisplatin followed...
What is the current status of trial NCT00004103?
This trial is currently completed. It is a Phase 2 study. The study started on 1998-07. Estimated completion is 2009-06.
What interventions are being tested in trial NCT00004103?
The interventions under investigation include: cisplatin (DRUG), conventional surgery (PROCEDURE), adjuvant therapy (PROCEDURE), floxuridine (DRUG), irinotecan hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00004103?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.